

Supplementary Table 3. Studies Reporting the Clinical Presentation in COVID-19 Patients with Underlying IBD and in General Population

| Variable | Lukin et al. ¹² | | Singh et al. ¹⁴ | |
|-----------------|-------------------------------|--------------------------|----------------------------------|---------------------------|
| | COVID-19 non-IBD (n = 160) | COVID-19 IBD (n = 80) | COVID-19 non-IBD (n = 19,776) | COVID-19 IBD (n = 232) |
| GI symptoms | | | | |
| Diarrhea | 31 (19.4) | 36 (45.0) | 1,018 (5.1) | 19 (8.2) |
| Vomiting | 10 (6.3) | 10 (12.5) | 813 (4.1) | 25 (10.7) |
| Nausea | 24 (15.0) | 12 (15.0) | 813 (4.1) | 25 (10.7) |
| Abdominal pain | 8 (5.0) | 16 (20.0) | 535 (2.7) | 18 (7.7) |
| Anorexia | 26 (16.3) | 7 (8.8) | NA | NA |
| Non-GI symptoms | | | | |
| Fever | 103 (64.4) | 53 (66.3) | 3,395 (17.2) | 38 (16.4) |
| Cough | 96 (60.0) | 54 (67.5) | 4,716 (23.8) | 56 (24.1) |
| Sore throat | NA | NA | 1,040 (5.3) | 14 (6.0) |
| Dyspnea | 70 (43.8) | 23 (28.8) | 2,827 (14.3) | 30 (12.9) |
| Ageusia | 7 (4.4) | 4 (5.0) | NA | NA |
| Anosmia | 7 (4.4) | 7 (8.8) | NA | NA |
| Fatigue | 44 (27.5) | 7 (8.8) | 1,167 (5.9) | 20 (8.6) |
| Myalgia | 44 (27.5) | 27 (8.8) | 1,167 (5.9) | 20 (8.6) |
| Running nose | NA | NA | NA | NA |
| Conjunctivitis | NA | NA | NA | NA |

Values are presented as number (%).

COVID-19, coronavirus disease 2019; IBD, inflammatory bowel disease; GI, gastrointestinal; NA, not available.